anonymous
Guest
anonymous
Guest
Gout is rare disease? Who knew????OP here. Gout team is rare disease so it’s confirmed that they will be under rare disease business unit.
Gout is rare disease? Who knew????OP here. Gout team is rare disease so it’s confirmed that they will be under rare disease business unit.
That is not true that nationally the majority of vials don’t have a PEF. It’s pretty easy to break out with data entered into PARC by PALs (number of infusions) vs vials, but there are plenty that don’t get them…yet again, there are undoubtedly some that are neph referrals, too, for which they get zero credit.
Also, the comment was about were the growth has come from, not overall business,
On a side note, it's beyond pathetic that more vials aren’t accompanied by PEFs. God only knows how many patients either pay more than they need to or don’t get on therapy because an infusion center tells them what their copay is and they back out. It is a thousand times easier here than when I sold an injectable drug to rheum. One of the SAMs on my team is just lazy AF. A little less than half of his PEFs have vials, and it’s from the same few providers who are easy to access but far away from his house. He has the lowest percentage PEFs by far and away on our team. It’s pretty sad because in those far away rural areas there are a lot of people that could use the financial help.
Because it's an infusion and is billed under medical most patients don't have much of a copay. Also offices don't do pets because of that and it only lengthens process. You sound like you just started.
Gout is rare disease? Who knew????
Wow, you sound like a very entitled person who has lost touch with reality (or has never had it) or does not understand managed care at all. Your version of “not much of a copay” is very different than that of the majority of the country. Out of curiosity, do you know the income of every patient infused?
Also, almost 50% of the Medicare population is now on a Medicare advantage plan, and the vast majority of those have a 20% coinsurance for part b drugs. About 10% of Medicare lives are straight Medicare w/o a supplement, so they have a 20% co-insurance. The other 40% have a supplement or are dual eligible, so, yes, their co-insurance is quite low. For commercial plans, the coinsurance can range significantly and can be huge. Plus, most plans have a deductible. Even a $40 copay is a lot to many people. Add that up for each infusion for a year and you’re almost at $1,000. That’s a lot of money for most Americans. So next time you see a vial come through with no PEF, I want you to think about people like my mom who are or were single parents who sacrificed everything for themselves yet still barely scraped to get by to provide for her kids. Now think of them in serious pain and having to sacrifice a significant amount of money FOR THEM if they want to get help for their insanely painful gout.
Your post seriously makes me sick. Patients first, my ass.
Amgen leadership coming for a town hall next week. Amgen peeps, what should we ask?
Do fat conservatives love liberal portions?Amgen leadership coming for a town hall next week. Amgen peeps, what should we ask?
Any Pharma company with sales incentives based on volume is not patient first, it’s sales first.
if you want to claim patient first, then incentives would need to be tied to outcomes or TTI.
no kidding. Clearly you missed the sarcasm. Hopefully Amgen doesn’t fall for the same BS that our leadership does regarding how supposedly difficult it is to get rheum’s to fill out a one page form. They were supposed to have a patient start (PEF required) component of IC starting this year but hosed leadership yet again.
Do alcoholic crows drink at the nest or a crow bar?Amgen leadership coming for a town hall next week. Amgen peeps, what should we ask?
Its not difficult but it lengthens the process. No office needs our hub or any hub. Fact.
And as far as the peasant that was complaining about medicare and copays- that is on the office not us. If the Dr. wants a copay help in the form of foundation or copay card for the patient they need to fill out the form.
And if you really want to debate what is best for patients...copay assistance should be illegal. It raises the cost of drugs and insurance.
Amgen leadership coming for a town hall next week. Amgen peeps, what should we ask?
you can ask any question if you yell loud enoughDo you seriously think that anyone is going to let you ask any question of importance? Do you think you will get any answer that will uncover something negative? Wow
The comment about cost was in response to the entitled jerk who said that the copays were “not that much”, jackass. It’s your job to continue to educate the doctor’s office about it. Plus, sometimes they forget. They have a lot to manage. Since you only seem to care about yourself, I will repeat the fact that there are undoubtedly multiple patients that have not perused therapy because after the infusion center told their their copay. Patients just assume there is no financial assistance, especially since infusion centers in hospitals do not give a crap if the patient gets infused or not. Plus, according to whatever data corporate has, patients stay on therapy longer with using our services. Numerous times I have had patients tell the PAL that they are going to quit due to flares and don’t even tell their doctors. My PAL has saved many discontinuations. So, entitled one, quit making excuses for your laziness. You are pathetic.
OP again... they should be giving more information on the closing date of the deal on the call next week. Rumored to be end of February. Still decisions need to be made with your inflammatory gout business unit and how that will ultimately look/fit in. All of other divisions will likely operate as normal moving forward. You all are very lucky as some of our best leadership culture wise will be in charge.
Thank you for this update. Do you know what decisions need to be made about the gout BU? I thought it was going to be in rare disease?OP again... they should be giving more information on the closing date of the deal on the call next week. Rumored to be end of February. Still decisions need to be made with your inflammatory gout business unit and how that will ultimately look/fit in. All of other divisions will likely operate as normal moving forward. You all are very lucky as some of our best leadership culture wise will be in charge.